TITLE

Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention

AUTHOR(S)
Fletcher, Barbara; Thalinger, Karen K.
PUB. DATE
October 2010
SOURCE
Critical Care Nurse;Oct2010, Vol. 30 Issue 5, p46
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the therapy for patients with acute coronary syndromes (ACS). It provides information on prasugrel, a new antiplatelet agent which offers an alternative pharmacological treatment and was recently cleared for marketing by the U.S. Food and Drug Administration. It also notes that by inhibiting platelet activation, the thienopyridine antiplatelet agents play a crucial role in the adjunctive treatment of patients with ACS.
ACCESSION #
54053227

 

Related Articles

  • Genotype-guided antiplatelet therapy dominant in the US.  // PharmacoEconomics & Outcomes News;3/31/2012, Issue 650, p3 

    The article reports on a study which found that genotype-guided antiplatelet therapy with either clopidogrel or prasugrel is more cost effective than prasugrel or clopidogrel used without genetic testing for the treatment of patients with acute coronary syndromes scheduled to undergo...

  • Prasugrel. Huber, Kurt; Yasothan, Uma; Hamad, Bashar; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jun2009, Vol. 8 Issue 6, p449 

    In February 2009, the antiplatelet therapy prasugrel (Efient; Daiichi Sankyo/Eli Lilly) was granted marketing authorization by the European Commission for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing primary or delayed percutaneous coronary...

  • DUAL ANTIPLATELET PLUS TIROFIBAN THERAPY HAVE A BENEFICIAL EFFECT ON ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION.  // Heart;Oct2010, pA162 

    An abstract of the article "Dual Antiplatelet Plus Tirofiban Therapy Have a Beneficial Effect on Acute Coronary Syndrome in Diabetic Patients Undergoing Percutaneous Coronary Intervention" by Shen Hua, and colleagues is presented.

  • PFT-guided antiplatelet therapy cost effective in ACS.  // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p14 

    The article discusses a study examining the cost effectiveness of an antiplatelet treatment for patients with acute coronary syndrome who are undergoing percutaneous coronary intervention.

  • Prasugrel in Clinical Practice. Bhatt, Deepak L. // New England Journal of Medicine;9/3/2009, Vol. 361 Issue 10, p940 

    The author discusses the U.S. Food and Drug Administration's approval of the thienopyridine prasugrel for patients who undergo percutaneous coronary intervention (PCI) for myocardial infarction or unstable angina. He says that this drug is designed to prevent consequent platelet aggregation and...

  • Antiplatelet therapy for secondary prevention of coronary artery disease. Pilgrim, Thomas; Windecker, Stephan // Postgraduate Medical Journal;May2015, Vol. 91 Issue 1075, p284 

    The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12...

  • Antiplatelet therapy for secondary prevention of coronary artery disease. Pilgrim, Thomas; Windecker, Stephan // Heart;Nov2014, Vol. 100 Issue 22, p1750 

    The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12...

  • TRIPLE VERSUS DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION.  // Heart;Oct2010, pA107 

    An abstract of the article "Triple Versus Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Percutanious Coronary Intervention" by Bin Hu and colleagues is presented.

  • Pharmacologic Therapy for Non ST-segment Elevation Acute Coronary Syndromes: Focus on Antithrombotic Therapy. Danchin, Nicolas; Aïssaoui, Nadia // Cardiovascular Drugs & Therapy;Aug2010, Vol. 24 Issue 4, p325 

    ntithrombotic therapy constitutes the basis of the management of acute coronary syndromes. It combines antiplatelet and anticoagulant therapy. Antiplatelet agents should combine aspirin and agents acting through the ADP pathway such as clopidogrel; newer antiplatelet agents such as prasugrel or...

  • Prasugrel. Duggan, Sean T.; Keating, Gillian M. // Drugs;2009, Vol. 69 Issue 12, p1707 

    Prasugrel (Efient®) is a potent, selective and irreversible inhibitor of adenosine diphosphate (ADP)-mediated platelet aggregation that is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) [comprising unstable angina...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics